A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age
Latest Information Update: 08 Mar 2026
At a glance
- Drugs GSK 4406371A (Primary) ; MMR-varicella zoster virus vaccine
- Indications Measles; Mumps; Rubella; Varicella zoster virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GSK
Most Recent Events
- 08 Mar 2026 New trial record